The Food and Pharmaceutical Bureau has approved the use of the kidney disease risk due to the deterioration of the dying due to the dying due to the dying due to end -stage kidney disease, and cardiovascular disease in patients with type 2 diabetes and chronic renal disease.
NOVO NORDISK announced its approval on Wednesday
Dr. Anna Windle, a senior vice president of Novo Nordisk’s clinical development, medicine and regulatory issues, stated: These combined diseases. Ozempic’s approval affects millions of adults and can have serious consequences if remaining without treatment -Kidney Metabolic syndrome can be dealt with more conditions in the metabolic syndrome. Masu. “
Approximately 37 million adults in Japan have chronic kidney disease known as CKD, and are expected to increase with aging groups.
Frequently related to type 2 diabetes, about 40 % of the type 2 people suffer from CKD.
With approval, doctors can prescribe Ozempic especially to treat CKDs in diabetic patients, New York Times It has been reported.
Studies that are examining the advantages of reducing the risk of CKD using Ozempic show that the risk of worsening renal function, which requires dialysis or transplantation, is 24 % lower than in placebo. The decrease in the kidneys has been slower than the patient using Ozen picks.
New York Times Ozempic reported that it has already been approved to reduce the risk of cardiovascular issues of both the treatment of type 2 diabetes and the history of diabetes and heart disease.
“It will be better as you can delay the decline in renal function,” said Dr. Melanie Hornig, kidney scholar. newspaper。 She said she had already prescribed some patients.
In the past, Era The doctor said, there were few options for diabetics to take medicine for blood pressure, blood sugar, and cholesterol, which could be higher in CKD. They also take other medicines to control swelling and manage iron, calcium and vitamin D.
At the same time, hyperglycemia can damage the blood vessels of the kidney.
© 2025 COX Media Group
